ATE346072T1 - Heterozyklische amidderivate mit glykogen- phosphorylase-hemmender wirkung - Google Patents

Heterozyklische amidderivate mit glykogen- phosphorylase-hemmender wirkung

Info

Publication number
ATE346072T1
ATE346072T1 AT03743418T AT03743418T ATE346072T1 AT E346072 T1 ATE346072 T1 AT E346072T1 AT 03743418 T AT03743418 T AT 03743418T AT 03743418 T AT03743418 T AT 03743418T AT E346072 T1 ATE346072 T1 AT E346072T1
Authority
AT
Austria
Prior art keywords
inhibiting effect
amide derivatives
glycogen phosphorylase
heterocyclic amide
phosphorylase inhibiting
Prior art date
Application number
AT03743418T
Other languages
English (en)
Inventor
Paul Robert Owen Whittamore
Park Alderley
Stuart Norman Lile Bennett
Iain Simpson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE346072T1 publication Critical patent/ATE346072T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03743418T 2002-03-06 2003-03-04 Heterozyklische amidderivate mit glykogen- phosphorylase-hemmender wirkung ATE346072T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0205170.4A GB0205170D0 (en) 2002-03-06 2002-03-06 Chemical compounds

Publications (1)

Publication Number Publication Date
ATE346072T1 true ATE346072T1 (de) 2006-12-15

Family

ID=9932334

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03743418T ATE346072T1 (de) 2002-03-06 2003-03-04 Heterozyklische amidderivate mit glykogen- phosphorylase-hemmender wirkung

Country Status (25)

Country Link
US (1) US7122567B2 (de)
EP (1) EP1483271B1 (de)
JP (1) JP2005524669A (de)
KR (1) KR20040091101A (de)
CN (1) CN1307183C (de)
AR (1) AR038886A1 (de)
AT (1) ATE346072T1 (de)
AU (1) AU2003209445A1 (de)
BR (1) BR0308145A (de)
CA (1) CA2477125A1 (de)
DE (1) DE60309849T2 (de)
DK (1) DK1483271T3 (de)
ES (1) ES2276092T3 (de)
GB (1) GB0205170D0 (de)
IL (1) IL163802A0 (de)
IS (1) IS7433A (de)
MX (1) MXPA04008611A (de)
NO (1) NO20044033L (de)
NZ (1) NZ534684A (de)
PL (1) PL372772A1 (de)
PT (1) PT1483271E (de)
RU (1) RU2004125145A (de)
TW (1) TW200306176A (de)
WO (1) WO2003074531A1 (de)
ZA (1) ZA200406685B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
JP4630267B2 (ja) * 2002-12-25 2011-02-09 第一三共株式会社 ジアミン誘導体
KR20050110612A (ko) * 2002-12-25 2005-11-23 다이이찌 세이야꾸 가부시기가이샤 디아민 유도체
GB0318463D0 (en) * 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0319759D0 (en) * 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
CA2551952A1 (en) 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole daao inhibitors
WO2006053274A2 (en) * 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
TWI281231B (en) * 2004-12-20 2007-05-11 Hynix Semiconductor Inc Method for forming storage node of capacitor in semiconductor device
CN104276955A (zh) 2006-01-06 2015-01-14 赛诺维信制药公司 基于四氢萘酮的单胺再摄取抑制剂
AU2007205114B2 (en) 2006-01-06 2012-11-08 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
CA2648121C (en) 2006-03-31 2013-08-06 Sepracor Inc. Preparation of chiral amides and amines
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
EP2617704B1 (de) 2007-05-31 2017-06-28 Sunovion Pharmaceuticals Inc. Phenyl-substituierte Cycloalkylamine als Monoamin-Wiederaufnahmehemmer

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE200740C (de)
US3706810A (en) * 1970-09-15 1972-12-19 American Cyanamid Co N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides
US4720503A (en) 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
US4668769A (en) 1985-08-02 1987-05-26 Hoover Dennis J Oxa- and azahomocyclostatine polypeptides
US4599198A (en) 1985-08-02 1986-07-08 Pfizer Inc. Intermediates in polypeptide synthesis
FR2601368B1 (fr) 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
DE3629545A1 (de) 1986-08-30 1988-03-10 Bayer Ag Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung
US4751231A (en) 1987-09-16 1988-06-14 Merck & Co., Inc. Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
JPH04179949A (ja) 1990-11-15 1992-06-26 Fuji Photo Film Co Ltd 新規な色素形成カプラーおよび該カプラーを用いたハロゲン化銀カラー写真感光材料
JP2668003B2 (ja) 1992-06-12 1997-10-27 ファイザー インク． ヒトの心臓キマーゼを含むアンギオテンシンｉキマーゼに関する阻害剤
ES2081747B1 (es) * 1993-09-07 1997-01-16 Esteve Labor Dr Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos.
US5863903A (en) 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
EP0749423B1 (de) 1994-03-09 2003-06-18 Novo Nordisk A/S Piperidine und pyrrolidine
FR2723739B1 (fr) 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
DE4445968A1 (de) 1994-12-22 1996-06-27 Bayer Ag Verwendung von Sulfonylguanazinen
CA2223625C (en) 1995-06-06 2003-06-03 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
ES2164151T3 (es) 1995-06-06 2002-02-16 Pfizer N-(indol-2-carbonil)glicinamidas sustituidas y derivados como inhibidores de la glucogeno fosforilasa.
CA2224062C (en) 1995-06-06 2001-09-04 Pfizer Limited Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
EP0858335B1 (de) 1995-09-08 2003-03-12 Novo Nordisk A/S 2-alkylpyrrolidine
WO1997031901A1 (en) 1996-02-29 1997-09-04 Mikael Bols Hydroxyhexahydropyridazines
EP0914322A1 (de) 1996-05-27 1999-05-12 Fujisawa Pharmaceutical Co., Ltd. Neue indolyl und benzofuranylcarboxamide als inhibitoren der stickoxidproduktion
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
JP2001505585A (ja) 1996-12-16 2001-04-24 藤沢薬品工業株式会社 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
WO1998040353A1 (en) 1997-03-07 1998-09-17 Novo Nordisk A/S Novel heterocyclic compounds
WO1998050359A1 (en) 1997-05-06 1998-11-12 Novo Nordisk A/S Novel heterocyclic compounds
UA57811C2 (uk) 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
EP0978279A1 (de) 1998-08-07 2000-02-09 Pfizer Products Inc. Glycogen-phosphorylase inhibitoren
WO2000042213A1 (en) 1999-01-13 2000-07-20 The Research Foundation Of State University Of New York A novel method for designing protein kinase inhibitors
AU2535700A (en) 1999-02-12 2000-08-29 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
JP3795305B2 (ja) 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
US6043091A (en) 1999-07-19 2000-03-28 Isis Pharmaceuticals Inc. Antisense modulation of liver glycogen phosphorylase expression
EP1220832A1 (de) 1999-09-29 2002-07-10 Novo Nordisk A/S Neue aromatische verbindungen
ES2211454T3 (es) 1999-09-30 2004-07-16 Pfizer Products Inc. Pirrolilamidas como inhibidores de la colageno fosforilasa.
SE9903998D0 (sv) 1999-11-03 1999-11-03 Astra Ab New compounds
PT1233962E (pt) 1999-11-05 2006-07-31 Sod Conseils Rech Applic Compostos heterociclicos e a sua utilizacao como medicamentos
ES2487897T3 (es) 2000-01-21 2014-08-25 Novartis Ag Combinaciones que consisten de inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6555569B2 (en) 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US20010053778A1 (en) 2000-03-16 2001-12-20 Hoover Dennis J. Pharmaceutical compositions of glycogen phosphorylase inhibitors
GT200100039A (es) 2000-03-16 2001-12-31 Pfizer Inhibidor de la glucogeno fosforilasa.
EP1136071A3 (de) 2000-03-22 2003-03-26 Pfizer Products Inc. Verwendung von Glykogen-Phosphorylase-Hemmern
DK1145717T3 (da) 2000-04-13 2004-08-02 Pfizer Prod Inc Synergistisk virkning af glyburid og milrinon
YU91002A (sh) 2000-06-09 2006-05-25 Aventis Pharma Deutschland Derivati acilfenil-karbamida, postupak za njihovu proizvodnju i njihova primena kao leka
US20020028826A1 (en) 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
IL144507A0 (en) 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
GB0021831D0 (en) 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
WO2002026714A1 (en) 2000-09-27 2002-04-04 Takeda Chemical Industries, Ltd. Spiro compounds
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
EP1338594A4 (de) 2000-11-01 2004-06-16 Shionogi & Co Pharmazeutische zusammensetzungen mit pgd2-rezeptor-antagonistischer wirkung
US20030147866A1 (en) 2001-04-04 2003-08-07 Nicolette Charles A. Novel BGP compounds for therapy and diagnosis and methods for using same
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
AU2002308706A1 (en) 2001-06-01 2002-12-16 Eli Lilly And Company Glp-1 formulations with protracted time action
EP1452526A1 (de) 2001-10-29 2004-09-01 Japan Tobacco Inc. Indolverbindung und deren medizinische verwendung
JP2005518365A (ja) 2001-11-27 2005-06-23 メルク　エンド　カムパニー　インコーポレーテッド ４−アミノキノリン化合物
MXPA03000966A (es) 2002-02-28 2003-09-04 Pfizer Prod Inc Agentes antidiabeticos.
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
JPWO2003091213A1 (ja) 2002-04-25 2005-09-02 アステラス製薬株式会社 新規なアミド誘導体又はその塩
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
JP2006507294A (ja) 2002-11-07 2006-03-02 ファイザー・プロダクツ・インク 抗糖尿病剤
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
JP2004196702A (ja) 2002-12-18 2004-07-15 Yamanouchi Pharmaceut Co Ltd 新規なアミド誘導体又はその塩
US7501440B2 (en) 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
MXPA05011176A (es) 2003-04-17 2005-12-14 Pfizer Prod Inc Derivados de carboxamida como agentes antidiabeticos.
BRPI0409952A (pt) 2003-04-30 2006-04-25 Pfizer Prod Inc agentes anti-diabéticos
WO2004113345A1 (ja) 2003-06-20 2004-12-29 Japan Tobacco Inc. 縮合ピロール化合物及びその医薬用途
GB0318464D0 (en) 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0318463D0 (en) 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0319690D0 (en) 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
GB0319759D0 (en) 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
WO2005020986A1 (en) 2003-08-29 2005-03-10 Astrazeneca Ab Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity
WO2005020985A1 (en) 2003-08-29 2005-03-10 Astrazeneca Ab Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
GB0320422D0 (en) 2003-08-30 2003-10-01 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
ES2276092T3 (es) 2007-06-16
GB0205170D0 (en) 2002-04-17
DK1483271T3 (da) 2007-02-19
CN1639167A (zh) 2005-07-13
HK1070365A1 (en) 2005-06-17
IS7433A (is) 2004-09-01
KR20040091101A (ko) 2004-10-27
PL372772A1 (en) 2005-08-08
NZ534684A (en) 2006-02-24
AU2003209445A1 (en) 2003-09-16
ZA200406685B (en) 2005-10-31
TW200306176A (en) 2003-11-16
NO20044033L (no) 2004-11-25
US20050131052A1 (en) 2005-06-16
MXPA04008611A (es) 2004-12-06
PT1483271E (pt) 2007-02-28
BR0308145A (pt) 2004-12-07
DE60309849T2 (de) 2007-06-14
JP2005524669A (ja) 2005-08-18
EP1483271B1 (de) 2006-11-22
WO2003074531A1 (en) 2003-09-12
RU2004125145A (ru) 2005-06-10
DE60309849D1 (de) 2007-01-04
IL163802A0 (en) 2005-12-18
US7122567B2 (en) 2006-10-17
EP1483271A1 (de) 2004-12-08
CN1307183C (zh) 2007-03-28
AR038886A1 (es) 2005-02-02
CA2477125A1 (en) 2003-09-12

Similar Documents

Publication Publication Date Title
ATE346072T1 (de) Heterozyklische amidderivate mit glykogen- phosphorylase-hemmender wirkung
NO20043852L (no) Heterocykliske amidderivater som inhibitorer av glykogen fosforylase
ATE404537T1 (de) Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung
DE602004009089D1 (de) Pyrrolderivate mit antibakterieller wirkung
NL300784I2 (nl) Ketorolac, of het trometamolzout ervan, en fenylefrine, of het hydrochloridezout ervan
ATE499347T1 (de) Amidderivate
DE60332125D1 (de) Indole mit antidiabetischer wirkung
ATE524474T1 (de) Aminderivate mit tyrosinkinase hemmender wirkung
LTC1427415I2 (lt) Laktamą turintys junginiai ir jų dariniai kaip xa faktoriaus inhibitoriai
NO20050077L (no) Substituerte heterocykliske derivater som er anvendelige som antidiabetes- og antiovervektsmidler
NO20055649D0 (no) Substituert dihydrokinazolin med antiviale egenskaper
ATE423117T1 (de) Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone
NO20044032L (no) Indolamidderivater med glykogenfosforylase inhibitorisk aktivitet
DK1652843T3 (da) Amidderivater
AU2003216991A8 (en) Indole amide derivatives and their use as glycogen phosphorylase inhibitors
DE60313622D1 (de) Indazol-aminoacetonitrilderivate mit pestizider wirkung
NO20054135D0 (no) Kipolinon/benzoksazin derivater og anvendelser derav
NO20054854D0 (no) Femrings heterocykliske derivater
ATE446750T1 (de) 3-cyano-chinolin-derivate mit antiproliferativer wirkung
DE60328272D1 (de) Diazabicycloalkan-derivate mit nk1-antagonistischer wirkung
DE60315984D1 (de) Substituierte benzisoxazolsulfonamide mit breitbändiger hiv-protease hemmender wirkung
AU2003212515A8 (en) Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
NO20023675D0 (no) Heterocykliske amidderivater
DE602004022445D1 (de) Dro-1h-pyrazol-derivaten mit cb1-antagonistischer wirkung und lipase-hemmern
SI1483271T1 (sl) Heterociklicni amidni derivati z glikogen fosforilazno inhibitorno aktivnostjo

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1483271

Country of ref document: EP

REN Ceased due to non-payment of the annual fee